UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000043275
Receipt number R000045243
Scientific Title Functional exploratory trial of symbiotic connection between food microorganism and oligosaccharide
Date of disclosure of the study information 2021/03/31
Last modified on 2022/03/08 17:54:45

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Functional exploratory trial of symbiotic connection between food microorganism and oligosaccharide

Acronym

Functional exploratory trial of symbiotic connection between food microorganism and oligosaccharide

Scientific Title

Functional exploratory trial of symbiotic connection between food microorganism and oligosaccharide

Scientific Title:Acronym

Functional exploratory trial of symbiotic connection between food microorganism and oligosaccharide

Region

Japan


Condition

Condition

Healthy male/female adults

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study is to examine some kind of effect on obesity-related indexes for elucidating the symbiotic connection between the food microorganism and oligosaccharide exploratorily, employing eighty healthy little-overweight subjects.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

1. Visceral fat area
2. Body fat percentage
3. Body fat mass
4. Body weight
5. Body mass index
6. Gut microbiota
7. Short chain fatty acids in blood and feces (acetic/propionic/n-butyric/iso-butyric/n-valeric/iso-valeric acids)
8. Gastrointestinal hormones (PYY, GLP-1, GIP, insulin)
9. Blood-biochemical test (Total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, blood glucose, and HbA1c)

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

4

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Oral ingestion of pro/prebiotics for 12 weeks.

Interventions/Control_2

Oral ingestion of probiotics for 12 weeks.

Interventions/Control_3

Oral ingestion of prebiotics for 12 weeks.

Interventions/Control_4

Oral ingestion of placebo for 12 weeks.

Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1) Male/female subjects ranging in age from 20 to 64 at informed consent.
2) Subjects ranging in BMI from 25.0 to <30.0 kg/m2.
3) Subjects who can give informed consent to participate in this trial after being provided with an explanation of the experimental protocol detail.

Key exclusion criteria

1) Subjects with previous/present medical history of serious diseases.
2) Subjects who contracted a digestive disease within the past two weeks, and are now under medical treatments.
3) Subjects with medical therapies for a lifestyle-related disease, such as diabetes, hypertension and dyslipidemia.
4) Subjects with milk allergy or suspicious one.
5) Pregnant, possibly pregnant during this trial, or lactating women.
6) Subjects falling into the habit of heavy smoking, excessive alcohol intake, and/or an irregular life rhythm.
7) Subjects taking steadily (not less than three times a week) in the health foods, probiotics, prebiotics, fermented milk and/or lactic acid beverages, which might affect the test results.
8) Subjects who took part in the other clinical/monitoring tests, except observing ones, within a month before giving informed consent to take part in this trial.
9) Others who have been determined as ineligible for participation in this trial, judging from the principal/sub investigator's opinions.

Target sample size

80


Research contact person

Name of lead principal investigator

1st name Shukuko
Middle name
Last name Ebihara

Organization

Chiyoda Paramedical Care Clinic

Division name

Director

Zip code

101-0047

Address

2F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan

TEL

03-5297-5548

Email

cpcc-contact@cpcc.co.jp


Public contact

Name of contact person

1st name Makoto
Middle name
Last name Ichinohe

Organization

CPCC Company Limited

Division name

Clinical Planning Department

Zip code

101-0047

Address

4F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan

TEL

03-5297-3112

Homepage URL


Email

cpcc-contact@cpcc.co.jp


Sponsor or person

Institute

CPCC Company Limited

Institute

Department

Personal name



Funding Source

Organization

Meiji Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of Chiyoda Paramedical Care Clinic

Address

2F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan

Tel

03-5297-5548

Email

IRB@cpcc.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 03 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2020 Year 10 Month 27 Day

Date of IRB

2020 Year 10 Month 29 Day

Anticipated trial start date

2021 Year 03 Month 31 Day

Last follow-up date

2021 Year 09 Month 06 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 02 Month 08 Day

Last modified on

2022 Year 03 Month 08 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045243


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name